Article
The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
Cancer - 1 Aug 2014
Zhao Mingchuan, Zhang Yishi, Cai Weijing, Li Jiayu, Zhou Fei, Cheng Ningning, Ren Ruixin, Zhao Chao, Li Xuefei, Ren Shengxiang, Zhou Caicun, Hirsch Fred R
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have EGFR mutations. Recent studies have indicated that some patients with positive mutations were refractory to EGFR TKIs if they harbored a B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (Bim) deletion polymorphism....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
